

ECFS Diagnostic Network Working Group

Coordinator: Nico Derichs, Berlin, Germany https://www.ecfs.eu/ecfs_dnwg

13th Annual Meeting, London, UK, 11 - 13th February 2016



Organizing Committee:

Jane Davies – Royal Brompton Hospital, London, UK
Nicholas Simmonds - Royal Brompton Hospital, London, UK

Nico Derichs – DNWG Coordinator Sheila Scheinert – DNWG Assistant

Scientific Program

Thursday 11 February 2016

- 13.30 Arrive and coffee
- 14.00 Welcome Jane Davies (London, UK)

<u>Session 1:</u> <u>When it's not CF: State of the art diagnostics for other chronic suppurative lung diseases</u>

(Chairs: Nick Simmonds, Isabelle Sermet-Gaudelus)

- 14.05 Advances in imaging of ciliary defects: EM, tomography and immunofluorescence Claire Hogg (London, UK)
- 14.35 An update in PCD genetics Hannah Mitchison (London, UK)
- 14.55 Immune testing in bronchiectasis Austin Worth (London, UK)
- 15.25 Secondary defects in CFTR in non-CF CSLD: myth or reality? Nasal PD and inflammatory cytokines in a cohort of patients with PCD Suzanne Crowley (Oslo, Norway & London, UK)
- 15.50 Discussion
- 16.00 Coffee break -

Session 2: Current practice and challenges of diagnosing CF in ...

(Chairs: Nico Derichs, Jacquelien Noordhoek)

- 16.30 Norway Olav Trond Storrøsten (Oslo, Norway)
- 16.45 Hungary Reka Bodnár (Budapest, Hungary)
- 17.00 Greece Elpis Hatziagorou (Thessaloniki, Greece)
- 17.15 Tunesia Samia Hamouda (Tunis, Tunesia)
- 17.30 How can CF Europe support diagnosing CF in European countries? (Jacquelien Noordhoek, CF Europe)

Friday 12 February 2016

Session 3: Precisely defining and communicating the diagnosis of CF and associated phenotypes

(Chairs: Kris De Boeck, Carlo Castellani)

- 9.00 CFF Diagnosis Consensus Statements 2016:
 - Screened populations Clement Ren (Indianapolis, USA)
 - Non-Screened populations Patrick Sosnay (Baltimore, USA)
- 9.45 CFTR-related disorder: extended use as label for multiorgan CF-like disease ("CFSPID developing symptoms/CFTR dysfunction/atypical CF") not fulfilling CF diagnostic criteria?
 - Pro: Kevin Southern (Liverpool, UK), Con: Jürg Barben (St. Gallen, Switzerland)
- 10.15 Discussion
- 10.50 Coffee break -
- 11.20 Why a diagnosis of CFSPID can be harder to handle than CF and how could we do better?

 Jane Davies, Dr Michele Puckey (Consultant Paediatric Psychologist) and CFSPID parents

 (London, UK)
- 12.00 CFSPID to CF: The perspective of the adult physician Nicholas Simmonds (London, UK)
- 12.30 ECFS Diagnosis Consensus Delphi Process 2016 Nico Derichs (Berlin, Germany)
- 13.00 Lunch break -

Session 4: Diagnostic use of CFTR Biomarker & Genetics

(Chairs: Michael Wilschanski, Inez Bronsveld)

- 14.00 Real life practice of sweat testing in Europe: Results of the ECFS DNWG survey and next steps Natalia Cirilli (Ancona, Italy)
- 14.30 How to define a CF-typical NPD? Multicenter reference data from the diagnostic ECFS NPD SOP validation study Isabelle Sermet-Gaudelus (Paris, France)

- 15.00 How to define a CF-typical ICM? Multicenter reference data from the diagnostic ECFS ICM SOP validation study and the ECFS CTN ICM certification process Sheila Scheinert (Berlin, Germany)
- 15.30 Young Investigator 1: Diagnostic application of ECFS SOPs for NPD and ICM to patients with questionable CF or CFTR-related disorder Michael Klosinski (Berlin, Germany)
- 15.45 Young Investigator 2: Organoids in a challenging diagnosis of atypical Cystic Fibrosis Barbara Bosch (Leuven, Belgium)
- 16.00 Coffee break -
- 16.30 Young Investigator 3: Combining standardized and new CFTR functional tests for diagnosis Silvia Vercellone (Verona, Italy)
- 16.45 Young Investigator 4: *Ex vivo* differentiated nasal epithelium as a model for the functional characterisation of splicing mutations in the *CFTR* gene and test of new targeted therapies?

 Anne Bergougnoux (Montpellier, France)
- 17.00 CFTR3: Collection of clinical phenotype data in subjects with rare *CFTR* mutations Elke De Wachter (Brussels, Belgium)
- 17.30 Quantifying CFTR function in intestinal organoids of subjects with rare *CFTR* mutations Anabela Ramalho (Leuven, Belgium)
- 18.00 Complete *CFTR* gene mutation analysis in European patients with CF Kris De Boeck (Leuven, Belgium)

Saturday 13 February 2016

Session 5: Clinical trials and outcome measures in CF

(Chairs: Kevin Southern, Elke De Wachter)

- 9.00 CFTR gene therapy: what does the future hold? Uta Griesenbach (London, UK)
- 9.30 Sweat test variability in real life Francois Vermeulen (Leuven, Belgium)
- 10.00 Lung clearance index: Update on the ECFS CTN Core facility and plans for a multicenter clinimetrics study Jane Davies (London, UK)
- 10.25 Further understanding differences between SF6 and nitrogen-based MBW techniques Katie Bayfield (London, UK)
- 10.50 Gastrointestinal outcome measures in CF clinical trials Michael Wilschanski (Jerusalem, Israel)
- 11.15 Coffee break -

Session 6: The ECFS Diagnostic Network Working Group - a growing global network

(Chairs: Jane Davies, Sheila Scheinert)

- 11.45 Diagnosing CF in Africa Refiloe Masekela (Durban, South Africa)
- 12.15 Young Investigator 5: A Molecular Investigation of Cystic Fibrosis in South Africa Cheryl Steward (Pretoria, South Africa)
- 12.30 Young Investigator 6: Pulsed direct and constant direct currents in the pilocarpine iontophoresis sweat chloride test Carla Gomez (Campinas, Brazil)
- 12.45 1st Latin American Newborn and Early Screening of CF patients (LANES) Meeting 2015: Summary and DNWG collaboration Ana Kotnik Pirs (Ljubljana, Slovenia)
- 13.00 Conclusion & DNWG perspectives Nico Derichs (Berlin, Germany)

The meeting is kindly supported by:



















The supporting companies had no input into the content development and program of the meeting.